Introduction – Addressing Core Exosome Isolation, Detection, and Disease Biomarker Needs
For translational researchers, diagnostic assay developers, and biopharmaceutical scientists, exosomes – nano-sized extracellular vesicles (30-150 nm) secreted by almost all cell types – are present in body fluids (blood, urine, cerebrospinal fluid (CSF), saliva, breast milk). Exosomes carry biomarkers (proteins, lipids, nucleic acids (mRNA, miRNA, DNA)) reflective of their cell of origin, making them attractive for liquid biopsy (non-invasive diagnostics) and therapeutic applications (drug delivery vehicles). However, isolating exosomes from complex biofluids and quantifying exosome-associated proteins (tetraspanins: CD9, CD63, CD81; other surface proteins: EpCAM, HER2, EGFR) requires specific, high-affinity antibodies. Exosome antigen antibodies – antibodies that specifically recognize and bind to specific proteins on the surface of exosomes (such as CD9, CD63, CD81 and other markers) – are often used for the separation, purification (immunocapture), quantitative detection (ELISA, flow cytometry, Western blot), and functional research of exosomes. They have important application value in the research and diagnosis of exosome biomarkers in the fields of cancer (early detection, monitoring treatment response), immunology (immune cell-derived exosomes), and neurodegenerative diseases (Alzheimer’s, Parkinson’s). Exosome antibodies are available as monoclonal (mono-specific, consistent, high specificity), polyclonal (recognize multiple epitopes, high sensitivity, can cross-react), and recombinant (engineered, batch consistency, animal-free production). As the exosome research field expands (over 10,000 exosome-related publications annually), liquid biopsy gains traction as a non-invasive alternative to tissue biopsy, and exosome-based therapeutics enter clinical trials (EV-based drug delivery), the market for exosome antibody reagents across biopharmaceutical research, medical diagnostics, clinical testing & CRO services, and other applications is growing rapidly. This deep-dive analysis integrates QYResearch’s latest forecasts (2026–2032), antibody type segmentation, and application-specific insights.
Global Leading Market Research Publisher QYResearch announces the release of its latest report “Exosome Antigen Antibody – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Exosome Antigen Antibody market, including market size, share, demand, industry development status, and forecasts for the next few years.
The global market for Exosome Antigen Antibody was estimated to be worth US96millionin2025andisprojectedtoreachUS96millionin2025andisprojectedtoreachUS 210 million, growing at a CAGR of 12.0% from 2026 to 2032. Exosome Antigen Antibody are antibodies that specifically recognize and bind to specific proteins on the surface of exosomes (such as CD9, CD63, CD81 and other markers), and are often used for the separation, purification, quantitative detection and functional research of exosomes. They have important application value in the research and diagnosis of exosome biomarkers in the fields of cancer, immunity, neurodegenerative diseases, etc.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6092083/exosome-antigen-antibody
Core Keywords (Embedded Throughout)
- Exosome antigen antibody
- CD9 antibody
- CD63 antibody
- Exosome isolation
- Liquid biopsy
Market Segmentation by Antibody Type and End-Use Sector
The exosome antigen antibody market is segmented below by both antibody class (type) and customer domain (application). Understanding this matrix is essential for antibody manufacturers targeting specific exosome applications (research, diagnostics, therapeutics).
By Type (Antibody Format / Specificity):
- Monoclonal Ab (mono-specific, single epitope. Produced by hybridoma. High consistency, low batch-to-batch variation. Used for exosome capture (immunoaffinity), flow cytometry, ELISA, Western blot. Higher specificity, lower cross-reactivity)
- Polyclonal Ab (multiple epitopes recognized. Produced by immunized animals (rabbit, goat). Higher sensitivity (multiple binding sites). May cross-react with non-target proteins. Used for Western blot, immunoprecipitation)
- Recombinant Ab (engineered (phage display), animal-free production. High batch-to-batch consistency, scalable. Can be designed as humanized. Emerging for exosome capture and therapeutics)
By Application:
- Biopharmaceutical Research (basic exosome biology (biogenesis, cargo sorting, intercellular communication), biomarker discovery (cancer, neurodegenerative), functional studies (immune modulation, angiogenesis))
- Medical Diagnostics (liquid biopsy: exosome-based biomarker detection for cancer (pancreatic, ovarian, lung, breast), neurological diseases (Alzheimer’s (tau, Aβ), Parkinson’s (α-synuclein)), infectious diseases (HIV, tuberculosis))
- Clinical Testing & CRO Services (contract research organizations offering exosome isolation and characterization (NTA (nanoparticle tracking analysis), TEM, Western blot, RNA-seq) as a service for pharma/biotech)
- Others (exosome-based therapeutics (drug delivery), vaccine development)
Industry Stratification: Exosome Research – Key Applications
Exosome capture using antibody-coated magnetic beads:
- Beads coated with anti-CD63 or anti-CD81 monoclonal antibodies.
- Incubated with biofluid (serum, urine, cell culture supernatant).
- Exosomes bound to beads, separated magnetically.
- Eluted exosomes used for downstream analysis (protein (Western blot), RNA (qPCR, sequencing), lipidomics).
Exosome quantification (ELISA, flow cytometry):
- Capture antibody (CD63) coated on plate.
- Exosomes from sample bound.
- Detection antibody (CD81 or CD9, conjugated to HRP or fluorophore).
- Signal quantified (exosome concentration).
Recent 6-Month Industry Data (September 2025 – February 2026)
- Exosome Antibody Market: 96Min2025,projected96Min2025,projected210M by 2032, 12.0% CAGR.
- Exosome Diagnostics (November 2025): Exosome Diagnostics (Bio-Techne) EXO100 (Prostate) test detects PCA3 and T2-ERG RNA in exosomes.
- ISEV Guidelines (December 2025): MISEV (Minimal Information for Studies of Extracellular Vesicles) recommends use of multiple tetraspanin antibodies (CD9, CD63, CD81) for exosome characterization.
- Innovation data (Q4 2025): Thermo Fisher “Exosome Isolation Kit (anti-CD63)” – magnetic beads, for exosome enrichment from serum/plasma. Compatible with Western blot, qPCR, NGS.
Typical User Case – Liquid Biopsy for Lung Cancer
A clinical research lab uses exosome antibody kit (anti-CD63-coated beads) to isolate exosomes from plasma of lung cancer patients.
Isolated exosomes: subjected to RNA-seq to identify early-stage lung cancer biomarkers (mutations, fusion genes).
Goal: develop non-invasive screening test for high-risk populations.
Technical Difficulties and Current Solutions
Despite promise, exosome antibody research faces four persistent technical hurdles:
- Exosome heterogeneity (different cell types produce exosomes with different surface markers). Use multiple antibodies (CD9, CD63, CD81).
- Non-exosomal vesicle co-isolation (microvesicles, apoptotic bodies). Ultracentrifugation (10,000g vs 100,000g).
- Antibody batch variability (polyclonal). Switch to monoclonal or recombinant.
- Cross-reactivity (non-specific binding). Validated antibodies (knockout validation).
Exclusive Industry Observation – The Exosome Antibody Market by Type and Application
Based on QYResearch’s interviews with 72 exosome researchers (October 2025 – January 2026), monoclonal antibodies most used (specificity, consistency); polyclonal for detection (sensitivity); recombinant emerging (scalable).
Monoclonal – 60% of antibody sales.
Recombinant – fastest growing (batch consistency).
For suppliers, key strategy: offer monoclonal antibodies against CD9, CD63, CD81 for exosome capture; recombinant antibodies for large-scale manufacturing.
Complete Market Segmentation (as per original data)
The Exosome Antigen Antibody market is segmented as below:
Major Players:
Abcam, Thermo Fisher Scientific, Bio-Techne, Santa Cruz Biotechnology, Cell Signaling Technology (CST), Proteintech, Merck, Miltenyi Biotec, Beijing Boaosjidian Biotechnology Co., Ltd., GenScript, Yeasen, Bio-Rad Laboratories, Novus Biologicals, GeneTex, Inc., Creative BioMart, Origene Technologies, Inc.
Segment by Type:
Monoclonal Ab, Polyclonal Ab, Recombinant Ab
Segment by Application:
Biopharmaceutical Research, Medical Diagnostics, Clinical Testing & CRO Services, Others
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
